From EU JCA to Local HTA
One European Assessment. Multiple National Decisions.
EU JCA creates a coordinated European clinical assessment, but it does not replace national HTA or pricing and reimbursement decision-making. For sponsors, that means the JCA dossier must be developed with the next stage already in mind. The challenge is to maximize the transferability of the European evidence package while anticipating where national bodies may require additional context, evidence, or analysis.
Cytel combines EU JCA expertise with substantial local HTA experience to help sponsors make that transition.
Talk to an EU JCA expertEU JCA is Not the End of the Access Journey
A JCA report provides a common clinical assessment, but national HTA bodies still need to determine how the evidence applies in their own decision-making environments. The implications can be significant. Countries may differ in their interpretation of evidence, relevant comparators, treatment pathways, economic considerations, and the degree to which additional local evidence is required. This means that local HTA should not be considered only after the JCA is complete. It needs to inform the evidence strategy from the beginning.
Build the Bridge Between EU and National Evidence
Cytel helps sponsors identify which elements of the JCA evidence package are likely to transfer directly into national submissions and where country-specific adaptation may be necessary.
Our teams can integrate national treatment patterns, HTA precedent, local evidence requirements, and methodological expectations into the broader evidence strategy. The result is a more deliberate transition from European assessment to country implementation.
This is particularly important in markets where national HTA methodology has strong implications for comparative evidence and value demonstration.
Germany, France, the Netherlands, and the UK
Cytel has extensive experience supporting local HTA activities in major European markets, including G-BA/IQWiG in Germany, HAS in France, ZIN in the Netherlands, and NICE/SMC in the UK.
The experience spans dossiers, advice interactions, hearings, economic evidence, model adaptations, RWE, and comparative evidence. Cytel’s local and in-country expertise gives the wider JCA team access to practical insight into how evidence is interpreted beyond the European assessment itself.
750+
HAS projects
200+
G-BA projects
40+
ZIN dossiers
20+
NICE/SMC dossiers
FAQs
Does EU JCA replace national HTA?
No. EU JCA addresses the coordinated clinical assessment, while national authorities continue to make country-level decisions on reimbursement, pricing and other local considerations.
Why involve national HTA experts before the JCA?
Because understanding national clinical practice, comparator expectations and methodological requirements can help sponsors identify evidence risks before the European assessment is finalized.
Can the JCA dossier be reused for national submissions?
Parts of the evidence can be transferred, but national submissions may require adaptation or additional evidence depending on country-specific methods and decision needs.
Why is Germany particularly important?
Germany is an important example of where the relationship between JCA evidence and national assessment needs careful planning. Cytel’s G-BA/IQWiG experience helps the team understand how European evidence can be translated into the German environment.
We help sponsors prepare for JCAs
Preparing for an upcoming EU JCA? Talk to Cytel’s experts about building an integrated evidence strategy.